- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: Genetics of obesity.
Displaying page 1 of 1.
EudraCT Number: 2006-005287-94 | Sponsor Protocol Number: Stulnig_PUFA1 | Start Date*: 2008-05-06 | |||||||||||
Sponsor Name:Medizinische Universität Wien | |||||||||||||
Full Title: Impact of n-3 Polyunsaturated Fatty Acids on Adipose Tissue Inflammation in Morbidly Obese Patients | |||||||||||||
Medical condition: morbid obesity | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005006-35 | Sponsor Protocol Number: RM-493-022 | Start Date*: 2018-05-30 |
Sponsor Name:Rhythm Pharmaceuticals, Inc. | ||
Full Title: Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 recepto... | ||
Medical condition: Patients with obesity caused by genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway. Human Genetics studies have identified several diseases that are the result of genet... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) GR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-004167-27 | Sponsor Protocol Number: RM-493-033 | Start Date*: 2022-03-02 | |||||||||||||||||||||
Sponsor Name:Rhythm Pharmaceuticals Limited | |||||||||||||||||||||||
Full Title: A Phase 3 Multi-Center, One-Year, Open-Label study of Setmelanotide in Pediatric Patients Aged 2 to <6 years of age with Rare Genetic Causes of Obesity | |||||||||||||||||||||||
Medical condition: POMC deficiency obesity due to mutations in the POMC gene PCSK1 deficiency due to mutations in the PCSK1 gene LEPR deficiency obesity due to mutations in the LEPR gene Bardet-Biedl syndrome | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Prematurely Ended) ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-005475-41 | Sponsor Protocol Number: MLX | Start Date*: 2014-11-05 |
Sponsor Name:UZ Brussel | ||
Full Title: Sulfamethoxazole treatment of primary PREPL deficiency | ||
Medical condition: Hypotonia-cystinuria syndrome and isolated PREPL deficiency. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002855-12 | Sponsor Protocol Number: RM-493-034 | Start Date*: 2022-04-22 |
Sponsor Name:Rhythm Pharmaceuticals Inc. | ||
Full Title: A 2-Stage (Open-Label Run-in followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled, Phase 2 study of Setmelanotide in Patients with Specific Gene Defects in the Melanocortin-4 Rece... | ||
Medical condition: Specific Gene Defects in the Melanocortin-4 Receptor Pathway, responsible for improper functions of certain messenger materials in the body. E.g Melanocyte-Stimulating Hormone (MSH) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) DE (Completed) ES (Ongoing) NL (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-002873-24 | Sponsor Protocol Number: RM-493-035 | Start Date*: 2022-05-16 |
Sponsor Name:Rhythm Pharmaceuticals Inc. | ||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study: 5 Independent Sub-studies of Setmelanotide in Patients with POMC, PCSK1, LEPR, SRC1, SH2B1, and PCSK1 N221D Gene Defects in the Melano... | ||
Medical condition: Specific Gene Defects in the Melanocortin-4 Receptor Pathway, responsible for improper functions of certain messenger materials in the body. E.g Melanocyte-Stimulating Hormone (MSH) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
